ImmunoOncology

Multiple Chinese biotechs are seeking to raise new funds through IPOs on the Hong Kong and Beijing stock exchanges to support international clinical trials for their first-in-class molecules.

The Phase II data for intismeran autogene in melanoma were mostly incremental, but the program’s continued success is a cornerstone of Moderna’s breakeven strategy.

Pilatus Biosciences' Switzerland-Taiwan-US structure exemplifies how biotechs might navigate US-China tensions, leveraging Chinese manufacturing efficiency while maintaining American investor credibility and partnership opportunities.

Deal Snapshot: Roche has scooped up a B7H3 ADC from China’s MediLink just a few months after Daiichi Sankyo temporarily halted enrolling patients in a pivotal Phase III trial with its same-class rival, Merck-partnered ifinatamab deruxtecan (I-DXd).

Hengrui’s relafupu-α (SHR-1701), a bifunctional fusion protein against PD-L1 and TGF-βR2, has been approved in China in combination with chemotherapy as a first-line treatment for HER2-negative, PD-L1-positive advanced gastric/gastroesophageal junction adenocarcinoma.

The Dallas-based biotech’s stock slumped by over 45% after it discontinued clinical development of AXN-2510 and gave the rights back to China’s ImmuneOnco.

Multiple novel combos of PD-(L)1 x VEGF-targeting bispecific antibodies and antibody-drug conjugates progressed through the clinic this year, many of which are from Chinese developers and with some advancing to first-line regimens.

J&J's late-breaking Phase III MajesTEC-3 data at the American Society of Hematology meeting highlighted curative potential for the bispecific T-cell engager in multiple myeloma.

To develop bispecific, dual-payload antibody-drug conjugates, Phrontline Biopharma’s strategy is to tune the activity of each payload to a similar level and engineer both toxins to fit within a branched linker, its CEO tells Scrip in an interview.

Next-gen CAR-T therapies showcased at the American Society of Hematology's annual meeting promise improved efficacy and safety, with Novartis, Gilead, and Kelonia advancing pivotal trials and exploring in vivo approaches.

The company plans to take IGV-001 to the FDA after the mid-stage trial showed a more than six-month improvement in overall survival compared with placebo.

The biotech will present data at the upcoming ASH meeting on three patients who achieved PRs or VGPRs with minimal residual disease negativity and no cases of neurotoxicity.